Related Experiment Video

Updated: Aug 5, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung

Yu-Chen Yang1, Can-Jun Zhao1, Zhao-Feng Jin2

  • 1Department of Traditional Chinese Medicine, Tangdu Hospital, Air Force Medical University, Xi'an, China.

Frontiers in Oncology
|March 27, 2023
PubMed

Insights

Ubiquitin-specific proteases (USPs) are key regulators in non-small-cell lung cancer (NSCLC) development. Targeting USPs with PROTACs and inhibitors offers promising new therapeutic strategies for NSCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Lung cancer, particularly non-small-cell lung cancer (NSCLC), has a high global mortality rate.
  • Conventional NSCLC treatments face challenges due to drug resistance and metastasis.
  • The ubiquitin-proteasome pathway (UPP) is crucial in tumor development, with ubiquitin-specific proteases (USPs) playing a significant role.

Purpose of the Study:

  • To review the role of USPs in NSCLC occurrence and progression.
  • To explore the therapeutic potential of targeting USPs in NSCLC.

Main Methods:

  • Literature review focusing on the ubiquitin-proteasome pathway and USPs in NSCLC.
  • Analysis of current and emerging targeted therapies, including PROTACs and small-molecule inhibitors.

Main Results:

  • USPs regulate protein degradation via deubiquitination, influencing NSCLC development.
  • Dysregulation of USPs can promote or inhibit tumor progression.
  • Targeting specific USPs presents a viable strategy for NSCLC treatment.

Conclusions:

  • USPs are critical regulators in NSCLC pathogenesis.
  • Targeted therapies like PROTACs and small-molecule inhibitors offer novel treatment avenues for NSCLC by modulating USP activity.
Keywords:
E3 ligaseNSCLCPROTACsUSPssignalling pathway

More Related Videos

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

2.6K
siRNA Screening to Identify Ubiquitin and Ubiquitin-like System Regulators of Biological Pathways in Cultured Mammalian Cells10:43

siRNA Screening to Identify Ubiquitin and Ubiquitin-like System Regulators of Biological Pathways in Cultured Mammalian Cells

Published on: May 24, 2014

11.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
919
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K